. With progression of the disease patients reach the terminal stage (ESRD) of chronic kidney disease. (4) There is currently no overall consensus regarding prediction of the rate of progression in ADPKD, especially in the early stage of disease largely due to the high degree of inter-patient variability. (5) 
OBjeCtives
This study aimed to adapt the ADPKD Outcomes Model (5, 6) in order to compare the progression to ESRD and relative costs of disease, comparing patients treated with the tolvaptan as to non-treated patients in Italy.
methODs
Utilising the structure of the ADPKD Outcomes Model (Figure 1 ) adapted to the Italian context, the analysis has simulated the evolution of ADPKD patients over a period of up to 80 years. The study was performed from both the Italian National Health Service (NHS) and social perspectives. The ADPKD Outcomes Model is based on a series of annual simulations at the individual patient level that allows clinical evolutions, such as the achievement of end-stage renal disease (ESRD) (Figure 1 ). The model is able to incorporate country-specific pathways for ESRD-affected patients, such as haemodialysis (HD), peritoneal dialysis (PD), transplant and conservative therapy (RRT), together with their different costs and mortality rates (Figure 2 ). Clinical data on the treatment effect of tolvaptan was derived from the TEMPO 3:4 clinical trial (7) .
ADAptiNG the ADpKD

ResUlts
The results show that tolvaptan is estimated to postpone the time to ESRD by a mean of around 3.7 years and increase life expectancy by a mean of 1.6 years. It is predicted that a large number of ESRD events and deaths could be avoided among patients treated with tolvaptan vs non-treated patients (346 ESRD events avoided and 68 deaths due to ESRD avoided at 15 years) (Figure 3 ).
It was also estimated (Figure 4 ) that, at 15 years, treatment with tolvaptan is estimated to increase the number of patients remaining in CKD stages 1-4 and reduce the number of patients in ESRD (i.e. 1070 patients non-treated in ESRD vs 361 patients treated with tolvaptan in ESRD at 15th year). Correspondingly, it was estimated that treatment with tolvaptan reduces the number of patients who need transplant, haemodialysis (HD), peritoneal dialysis (PD) or conservative care ( Figure 5 ). 
CONClUsiONs
The use of tolvaptan in patients with ADPKD is estimated to permit a slowing down in the worsening of the disease, increasing life expectancy and the achievement of a considerable decrease in the direct and indirect health costs in the medium to long-term 
